Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Director departure
Inv. presentation

Immunovant, Inc. (IMVT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/06/2023 4 Butchko Julia G. (Chief Development Officer) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 296 shares @ $35.54, valued at $10.5k
Sold 1,439 shares @ $36.39, valued at $52.4k
10/06/2023 4 Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 894 shares @ $35.54, valued at $31.8k
Sold 4,345 shares @ $36.39, valued at $158.1k
10/04/2023 SC 13D/A Roivant Sciences Ltd. reports a 55.3% stake in Immunovant, Inc.
10/04/2023 4 Roivant Sciences Ltd. (10% Owner) has filed a Form 4 on Immunovant, Inc.
Txns: Granted 4,473,684 shares @ $38, valued at $170M
Bought 1,526,316 shares @ $38, valued at $58M
09/29/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/28/2023 8-K Quarterly results
09/28/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
09/26/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
09/26/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/25/2023 4 Levine Mark S. (Chief Legal Officer) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 12,285 shares @ $20.3, valued at $249.4k
Sold 1 shares @ $20.89, valued at $20.9
08/25/2023 4 Barnett Eva Renee (CFO) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 14,385 shares @ $20.3, valued at $292k
Sold 1 shares @ $20.89, valued at $20.9
08/25/2023 4 Butchko Julia G. (Chief Development Officer) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 12,332 shares @ $20.3, valued at $250.3k
Sold 1 shares @ $20.89, valued at $20.9
08/25/2023 4 Macias William L. (Chief Medical Officer) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 12,332 shares @ $20.3, valued at $250.3k
Sold 1 shares @ $20.89, valued at $20.9
08/23/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/16/2023 4 Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 91,744 shares @ $21.34, valued at $2M
Sold 11,314 shares @ $22.04, valued at $249.4k
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023"
08/08/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/27/2023 4 Levine Mark S. (Chief Legal Officer) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 3,917 shares @ $21.63, valued at $84.7k
07/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/13/2023 4 Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 3,233 shares @ $19.73, valued at $63.8k
07/13/2023 4 Butchko Julia G. (Chief Development Officer) has filed a Form 4 on Immunovant, Inc.
Txns: Sold 1,470 shares @ $19.73, valued at $29k
04/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/19/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy